EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer

Anna Julie Kjøl Høyvik, Monika Kvassheim, Li-Wei Ma, Elisabeth Wiig, Tiril Hillestad, Mona-Elisabeth Revheim, Rugile Liukaityte, Øyvind Bruland, Asta Juzeniene iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07330-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Anna Julie Kjøl Høyvik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, 0379, Norway. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 1-Ring, Dipeptides, Lutetium, Lead Radioisotopes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oslo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [ 177 Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease. The alpha-emitting radioligand [ 212 Pb]Pb-AB001 could offer enhanced treatment by delivering high energy over a short range. This study compared the efficacy of [ 212 Pb]Pb-AB001 and [ 177 Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.

Methods

Binding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24‒1.0 MBq [ 212 Pb]Pb-AB001 or 22‒66 MBq [ 177 Lu]Lu-PSMA-617 were initiated 7 d post-cell inoculation. Metastatic burden was measured using bioluminescence imaging, and PSMA-targeted uptake was determined with [ 18 F]F-PSMA-1007 µPET/µCT. Gamma-autoradiography evaluated [ 212 Pb]Pb-AB001 distribution, and bone metastases were identified by radiography.

Results

Both radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. µPET/µCT demonstrated increased [ 18 F]F-PSMA-1007 uptake in metastases, matching the bioluminescence imaging results. Focal [ 212 Pb]Pb-AB001 distribution in the metastatic xenograft indicated heterogeneously distributed micrometastases in the organs. A median survival up to 47 d was achieved with [ 212 Pb]Pb-AB001, compared to 25 d for controls and 27 d for [ 177 Lu]Lu-PSMA-617. An activity-dependent reduction in bone metastases was observed for [ 177 Lu]Lu-PSMA-617, while no bone lesions were detected in [ 212 Pb]Pb-AB001-treated mice. Conclusion [ 212 Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [ 177 Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 1-RingDipeptidesLutetiumLead RadioisotopesProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsAnimalsMaleMiceHumansDisease Models, AnimalCell Line, TumorTissue DistributionNeoplasm MetastasisProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu212PbDisseminated prostate cancer modelPSMATargeted alpha therapy

Substanzen

Heterocyclic Compounds, 1-RingDipeptidesLutetiumPSMA-617Lutetium-177Lead RadioisotopesRadioisotopesLead-212RadiopharmaceuticalsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, 0379, Norway.
  • ARTBIO AS, Oslo, 0379, Norway.
  • Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, 0318, Norway.
  • Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, 0379, Norway.
  • Department of Core Facilities, Institute for Cancer Research and Molecular Imaging, Oslo University Hospital, Oslo, 0379, Norway.
  • The Intervention Centre, Oslo University Hospital, Oslo, 0372, Norway.

ORCID-Profile: Asta Juzeniene

Förderung

  • University of Oslo

Zitieren

APA

Høyvik, A. J. K., Kvassheim, M., Ma, L. W., Wiig, E., Hillestad, T., Revheim, M. E., Liukaityte, R., Bruland, Ø., & Juzeniene, A. (2025). Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07330-y

Vancouver

Høyvik AJK, Kvassheim M, Ma LW, Wiig E, Hillestad T, Revheim ME, et al. Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07330-y

BibTeX
@article{Hyvik2025,
  author = {Høyvik, Anna Julie Kjøl and Kvassheim, Monika and Ma, Li-Wei and Wiig, Elisabeth and Hillestad, Tiril and Revheim, Mona-Elisabeth and Liukaityte, Rugile and Bruland, Øyvind and Juzeniene, Asta},
  title = {Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07330-y}
}
Kostenlos starten →